BiotechTube
Aptatek BioSciences

Aptatek BioSciences

Philadelphia, United States· Est.
aptatek.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Aptatek BioSciences is a private, pre-revenue diagnostics company founded in 2014 and headquartered in Philadelphia. It is developing the Aptatek HomeCheck System, a portable diagnostic platform that uses DNA aptamers to detect small-molecule biomarkers with clinical lab sensitivity, starting with an FDA-designated Breakthrough Device for PKU monitoring. The technology, licensed from Columbia University, aims to decentralize testing for chronic conditions, allowing for immediate dietary or medication adjustments. The company is led by CEO Michael Boyce-Jacino and is supported by a scientific team including the technology's academic founders.

Metabolic Disorders

Technology Platform

Proprietary DNA aptamer assay technology integrated into a handheld, smartphone-connected diagnostic device for detecting small-molecule biomarkers with lab-quality sensitivity and specificity.

Funding History

2
Total raised:$3.5M
Grant$1.5M
Seed$2M

Opportunities

The primary opportunity is to dominate the home-monitoring niche for PKU, a condition with a high unmet need for rapid testing.
The flexible aptamer platform then allows for rapid expansion into monitoring other rare metabolic diseases and broader chronic conditions (e.g., therapeutic drug monitoring, kidney disease), accessing large point-of-care diagnostics markets.

Risk Factors

Key risks include failure to obtain FDA clearance despite Breakthrough designation, challenges in securing insurance reimbursement for a novel home test, and slower-than-expected adoption by patients and clinicians.
There is also platform risk if expansion into other biomarkers proves technically or commercially difficult.

Competitive Landscape

Direct competition in home PKU testing is limited, with the main alternative being central lab blood spot testing. Broader competition comes from other point-of-care diagnostic companies using different technologies (e.g., immunoassays, microfluidics) for decentralized testing. Aptatek's key differentiator is its aptamer-based ability to detect small molecules at lab quality in a portable format.

More companies in Diagnostics & Precision Medicine →More companies in United States →